[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100404333":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":55,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":71,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":10,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chemotherapy",null,"Patients treated with palliative chemotherapy",[13],"Drug: cisplatin-based chemotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","cisplatin-based chemotherapy","GP: cisplatin 80 mg\u002Fm2 intravenous infusion on day1, gemcitabine 1000 mg\u002Fm2 intravenous infusion on day 1 and 8, both drugs are given every 3 weeks, recommended 6 cycles.\n\nTP: cisplatin 75 mg\u002Fm2 intravenous infusion in day1, docetaxel 75 mg\u002Fm2 intravenous infusion in day 1, both drugs are given every 3 weeks, recommended 6 cycles.\n\nPF: cisplatin 100 mg\u002Fm2 intravenous infusion in day1, fluorouracil 4000 mg\u002Fm2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.\n\nTPF: cisplatin 60 mg\u002Fm2 intravenous infusion in day1, docetaxel 60 mg\u002Fm2 intravenous infusion in day 1, fluorouracil 3000 mg\u002Fm2 intravenous infusion in day 1 to 5, both drugs are given every 3 weeks, recommended 6 cycles.\n\nChoice of chemotherapy regimen is decided by patient's doctor in charge.",[9],[21,22,23,24],"docetaxel and cisplatin","fluorouracil and cisplatin","docetaxel, fluorouracil and cisplatin","gemcitabine and cisplatin",[26],{"name":27,"affiliation":5,"role":28},"Chong Zhao, M.D","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":10,"email":34},"Jingjing Miao, M.D","CONTACT","86-13631355201","miaojingjing90@163.com",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Cancer Center, Sun Yat-sen University","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":45,"coordinates":46},"Point",[47,48],113.25,23.11667,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":53,"phoneExt":10,"email":54},"Chong Zhao","02087342638","zhaochong@sysucc.org.cn",{"type":28,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Zhao Chong","Prof.","100404333","detecting-chemosensitivity-and-predicting-treatmemt-efficacy-with-ctcs-in-mnpc-100404333",false,"NCT04544969","Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC","Detecting Chemosensitivity and Predicting Treatmemt Efficacy With Circulating Tumour Cells From Peripheral Blood in Metastatic Nasopharyngeal Carcinoma Patients","Inclusion Criteria:\n\n* NPC patients with distant metastasis after 3 months of primary radiotherapy, and not suitable for local treatment\n* At least having one measurable metastatic lesion\n* All genders，range from 18～70 years old\n* ECOG score 0 \\~ 1\n* Expected survival time ≥ 3 months\n* White blood cell(WBC) count ≥ 3×109\u002FL, neutrophile granulocyte(NE) count ≥ 1.5×109\u002FL, hemoglobin(HGB) ≥ 90g\u002FL, platelet(PLT) count ≥ 100×109\u002FL\n* Alanine aminotransferase (ALT) or aspartate aminotransferase(AST) \\\u003C 2.5×upper limit of normal(ULN), bilirubin(BUN) or creatinine(CRE) \\\u003C 1.5×ULN, alanine aminotransferase (CCR) ≥ 60ml\u002Fmin\n* Inform consent form\n\nExclusion Criteria:\n\n* Have or are suffering from other malignant tumors;\n* Participating in other clinical trials;\n* Drug or alcohol addition;\n* Do not have full capacity for civil acts;\n* Mental disorder;\n* Pregnancy or lactation;\n* Severe complication, eg, uncontrolled hypertension.","ALL","18 Years","70 Years",{"count":69,"type":70},50,"ESTIMATED","1 Year","OBSERVATIONAL","The prospective observational clinical study will recruit 50 metastatic nasopharyngeal carcinoma (mNPC) patients, detecting patient's chemosensitivity with the circulating tumor cells (CTCs) from peripheral blood and prdicting patient's treatment efficacy with CTCs dynamic change.",[75,76,77,78],"Circulating Tumor Cell","Nasopharyngeal Carcinoma","Distant Metastases.Clinical","Effects of Chemotherapy","2025-01-25",{"date":81,"type":82},"2025-01-28","ACTUAL",{"date":84,"type":82},"2020-04-01",{"date":86,"type":70},"2027-12-31",{"name":5,"class":6},1]